Rodger  Novak net worth and biography

Rodger Novak Biography and Net Worth

President of CRISPR Therapeutics

Dr. Rodger Novak is the co-founder, president and chairman of CRISPR Therapeutics, a Switzerland-based biotechnology company he helped found in 2013. 

Since its inception in 2013, Dr. Novak has been at the helm of CRISPR and its emerging technologies. From 2013 to 2017 Dr. Novak served as the company’s CEO, helping turn CRISPR into a clinical stage company by building up its U.S.-based operations to more than 150 employees and taking the company public in 2016.

During his tenure as CEO, Dr. Novak helped raise more than $400 million in capital, established a joint venture with Bayer and closed a multi-billion dollar deal with Vertex Pharmaceuticals. 

He left his position as CEO in December 2017 to serve as the company’s president and chairman of the board. He also serves as the director of Casebia Therapeutics, CRISPR’s joint venture with Bayer AG. 

Dr. Novak was a serial entrepreneur and experienced pharmaceutical and biotechnology executive long before CRISPR’s founding. He previously served as the global head of infectious disease and research and development with Sanofi, based in Paris. While there, he was tasked with discovery and R&D around antibiotics, antivirals and drugs for the diseases present in the developing world. 

In 2006, he co-founded Nabriva Therapeutics, an antibacterial development company operating out of Vienna, Austria. He served as chief operating officer at Nabriva for almost six years. Dr. Novak’s career began at Sandoz, where he worked as the deputy head of the antibiotic research institute. Nabriva is largely a spin-off of Dr. Novak’s work at Sandoz. 

He is also a former professor of microbiology at the Vienna Biocenter in Austria. He earned his M.D. from Philipps University in Marburg, Germany and his U.S. medical license the following year. Dr. Novak continued his post-doctoral work in New York City, serving at The Rockefeller University, St. Jude’s Children’s Research Hospital and the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center. 

He is listed as co-inventor for five patents, and he has authored articles for Nature, Molecular Cell, and Nature Medicine

What is Rodger Novak's net worth?

The estimated net worth of Rodger Novak is at least $39.06 million as of June 30th, 2021. Dr. Novak owns 573,007 shares of CRISPR Therapeutics stock worth more than $39,056,157 as of March 28th. This net worth estimate does not reflect any other assets that Dr. Novak may own. Learn More about Rodger Novak's net worth.

How old is Rodger Novak?

Dr. Novak is currently 55 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. The oldest executive at CRISPR Therapeutics is Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member, who is 56 years old. Learn More on Rodger Novak's age.

How do I contact Rodger Novak?

The corporate mailing address for Dr. Novak and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on Rodger Novak's contact information.

Has Rodger Novak been buying or selling shares of CRISPR Therapeutics?

Rodger Novak has not been actively trading shares of CRISPR Therapeutics during the last ninety days. Most recently, Rodger Novak sold 25,000 shares of the business's stock in a transaction on Wednesday, June 30th. The shares were sold at an average price of $165.00, for a transaction totalling $4,125,000.00. Following the completion of the sale, the president now directly owns 573,007 shares of the company's stock, valued at $94,546,155. Learn More on Rodger Novak's trading history.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, insiders at the sold shares 12 times. They sold a total of 209,410 shares worth more than $13,234,926.95. The most recent insider tranaction occured on March, 15th when CFO Raju Prasad sold 3,524 shares worth more than $256,159.56. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.

Information on this page was last updated on 3/15/2024.

Rodger Novak Insider Trading History at CRISPR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2021Sell25,000$165.00$4,125,000.00573,007View SEC Filing Icon  
6/21/2021Sell25,000$128.62$3,215,500.00646,836View SEC Filing Icon  
11/30/2020Sell100,000$125.00$12,500,000.00698,007View SEC Filing Icon  
9/1/2020Sell25,000$92.62$2,315,500.00651,940View SEC Filing Icon  
7/7/2020Sell25,000$90.00$2,250,000.00653,593View SEC Filing Icon  
6/23/2020Sell50,000$75.00$3,750,000.00698,007View SEC Filing Icon  
5/19/2020Sell50,000$65.00$3,250,000.00798,007View SEC Filing Icon  
11/19/2019Sell33,618$70.00$2,353,260.0033,618View SEC Filing Icon  
7/10/2019Sell50,000$50.00$2,500,000.00848,007View SEC Filing Icon  
6/10/2019Sell50,000$45.00$2,250,000.00898,007View SEC Filing Icon  
3/4/2019Sell85,220$40.40$3,442,888.001,024,534View SEC Filing Icon  
3/1/2019Sell8,693$40.01$347,806.931,024,534View SEC Filing Icon  
2/25/2019Sell14,780$40.00$591,200.001,033,227View SEC Filing Icon  
1/8/2019Sell17,310$35.09$607,407.901,130,697View SEC Filing Icon  
5/17/2018Sell75,000$60.00$4,500,000.001,183,247View SEC Filing Icon  
9/5/2017Sell18,470$20.76$383,437.201,148,007View SEC Filing Icon  
8/30/2017Sell75,795$20.25$1,534,848.751,232,697View SEC Filing Icon  
6/22/2017Sell10,825$15.37$166,380.251,225,830View SEC Filing Icon  
6/21/2017Sell30,222$15.01$453,632.221,230,397View SEC Filing Icon  
6/9/2017Sell5,303$15.02$79,651.061,219,208View SEC Filing Icon  
5/30/2017Sell3,650$15.02$54,823.001,218,655View SEC Filing Icon  
5/17/2017Sell50,000$16.26$813,000.001,239,082View SEC Filing Icon  
5/5/2017Sell616$16.92$10,422.721,215,621View SEC Filing Icon  
5/4/2017Sell49,384$16.30$804,959.201,230,929View SEC Filing Icon  
4/20/2017Sell50,000$17.88$894,000.001,262,711View SEC Filing Icon  
See Full Table

Rodger Novak Buying and Selling Activity at CRISPR Therapeutics

This chart shows Rodger Novak's buying and selling at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $68.16
Low: $67.52
High: $70.12

50 Day Range

MA: $73.90
Low: $61.01
High: $89.12

2 Week Range

Now: $68.16
Low: $37.55
High: $91.10

Volume

1,600,516 shs

Average Volume

1,966,590 shs

Market Capitalization

$5.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79